Logo image of HCAT

HEALTH CATALYST INC (HCAT) Stock Fundamental Analysis

NASDAQ:HCAT - Nasdaq - US42225T1079 - Common Stock - Currency: USD

3.65  -0.1 (-2.67%)

After market: 3.65 0 (0%)

Fundamental Rating

3

Taking everything into account, HCAT scores 3 out of 10 in our fundamental rating. HCAT was compared to 36 industry peers in the Health Care Technology industry. HCAT has a bad profitability rating. Also its financial health evaluation is rather negative. HCAT is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HCAT was profitable.
HCAT had a positive operating cash flow in the past year.
In the past 5 years HCAT always reported negative net income.
In the past 5 years HCAT reported 4 times negative operating cash flow.
HCAT Yearly Net Income VS EBIT VS OCF VS FCFHCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

HCAT has a better Return On Assets (-8.15%) than 66.67% of its industry peers.
With a Return On Equity value of -19.28%, HCAT perfoms like the industry average, outperforming 52.78% of the companies in the same industry.
Industry RankSector Rank
ROA -8.15%
ROE -19.28%
ROIC N/A
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
HCAT Yearly ROA, ROE, ROICHCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

With a Gross Margin value of 45.94%, HCAT is not doing good in the industry: 61.11% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of HCAT has declined.
The Profit Margin and Operating Margin are not available for HCAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
HCAT Yearly Profit, Operating, Gross MarginsHCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HCAT has more shares outstanding
The number of shares outstanding for HCAT has been increased compared to 5 years ago.
HCAT has a worse debt/assets ratio than last year.
HCAT Yearly Shares OutstandingHCAT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HCAT Yearly Total Debt VS Total AssetsHCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.32, we must say that HCAT is in the distress zone and has some risk of bankruptcy.
HCAT has a worse Altman-Z score (-1.32) than 63.89% of its industry peers.
HCAT has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
HCAT has a worse Debt to Equity ratio (0.40) than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z -1.32
ROIC/WACCN/A
WACC8.72%
HCAT Yearly LT Debt VS Equity VS FCFHCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 1.24 indicates that HCAT should not have too much problems paying its short term obligations.
HCAT has a worse Current ratio (1.24) than 66.67% of its industry peers.
HCAT has a Quick Ratio of 1.24. This is a normal value and indicates that HCAT is financially healthy and should not expect problems in meeting its short term obligations.
HCAT's Quick ratio of 1.24 is on the low side compared to the rest of the industry. HCAT is outperformed by 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.24
Quick Ratio 1.24
HCAT Yearly Current Assets VS Current LiabilitesHCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

HCAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.00%, which is quite impressive.
The Revenue has been growing slightly by 4.88% in the past year.
Measured over the past years, HCAT shows a quite strong growth in Revenue. The Revenue has been growing by 14.63% on average per year.
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)4.88%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%6.28%

3.2 Future

Based on estimates for the next years, HCAT will show a very strong growth in Earnings Per Share. The EPS will grow by 28.57% on average per year.
The Revenue is expected to grow by 11.38% on average over the next years. This is quite good.
EPS Next Y-12.94%
EPS Next 2Y17.13%
EPS Next 3Y32.08%
EPS Next 5Y28.57%
Revenue Next Year8.94%
Revenue Next 2Y9.1%
Revenue Next 3Y9.49%
Revenue Next 5Y11.38%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HCAT Yearly Revenue VS EstimatesHCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M
HCAT Yearly EPS VS EstimatesHCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 15.21, HCAT is valued correctly.
94.44% of the companies in the same industry are more expensive than HCAT, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.50. HCAT is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 9.50, the valuation of HCAT can be described as reasonable.
Based on the Price/Forward Earnings ratio, HCAT is valued cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of HCAT to the average of the S&P500 Index (36.44), we can say HCAT is valued rather cheaply.
Industry RankSector Rank
PE 15.21
Fwd PE 9.5
HCAT Price Earnings VS Forward Price EarningsHCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCAT Per share dataHCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

HCAT's earnings are expected to grow with 32.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.13%
EPS Next 3Y32.08%

More info and screens

0

5. Dividend

5.1 Amount

HCAT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEALTH CATALYST INC

NASDAQ:HCAT (7/18/2025, 8:00:01 PM)

After market: 3.65 0 (0%)

3.65

-0.1 (-2.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners80.7%
Inst Owner Change0%
Ins Owners2.85%
Ins Owner Change17.04%
Market Cap254.04M
Analysts77.89
Price Target7.93 (117.26%)
Short Float %5.29%
Short Ratio6.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)171.62%
Min EPS beat(2)-46.95%
Max EPS beat(2)390.2%
EPS beat(4)2
Avg EPS beat(4)90.46%
Min EPS beat(4)-46.95%
Max EPS beat(4)390.2%
EPS beat(8)6
Avg EPS beat(8)599.06%
EPS beat(12)10
Avg EPS beat(12)431.21%
EPS beat(16)14
Avg EPS beat(16)334.63%
Revenue beat(2)0
Avg Revenue beat(2)-1.85%
Min Revenue beat(2)-2.04%
Max Revenue beat(2)-1.66%
Revenue beat(4)0
Avg Revenue beat(4)-1.59%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)-0.79%
Revenue beat(8)1
Avg Revenue beat(8)-1.26%
Revenue beat(12)3
Avg Revenue beat(12)-0.8%
Revenue beat(16)6
Avg Revenue beat(16)-0.35%
PT rev (1m)-2.78%
PT rev (3m)5.11%
EPS NQ rev (1m)-15.06%
EPS NQ rev (3m)-57.91%
EPS NY rev (1m)-18.76%
EPS NY rev (3m)-17.28%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-2.73%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.17%
Valuation
Industry RankSector Rank
PE 15.21
Fwd PE 9.5
P/S 0.82
P/FCF N/A
P/OCF 55.55
P/B 0.67
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.24
EY6.58%
EPS(NY)0.38
Fwd EY10.53%
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)0.07
OCFY1.8%
SpS4.47
BVpS5.41
TBVpS-0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.15%
ROE -19.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.94%
FCFM N/A
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
F-Score6
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.74%
Cap/Sales 6.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.24
Quick Ratio 1.24
Altman-Z -1.32
F-Score6
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)36.51%
Cap/Depr(5y)42.93%
Cap/Sales(3y)5.5%
Cap/Sales(5y)5.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y-12.94%
EPS Next 2Y17.13%
EPS Next 3Y32.08%
EPS Next 5Y28.57%
Revenue 1Y (TTM)4.88%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%6.28%
Revenue Next Year8.94%
Revenue Next 2Y9.1%
Revenue Next 3Y9.49%
Revenue Next 5Y11.38%
EBIT growth 1Y39.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.56%
EBIT Next 3Y44.79%
EBIT Next 5Y33.73%
FCF growth 1Y75.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y110.89%
OCF growth 3YN/A
OCF growth 5YN/A